The treatment and prevention of mouse melanoma with an oral dna vaccine carried by attenuated salmonella typhimurium

Journal of Immunotherapy

Volumn 33, Issue 5, 2010, Pages 453-460

  Zhu, Xiangying ^a   Cai, Jianguo ^a   Huang, Jiajie ^a   Jiang, Xinyin ^a   Ren, Daming ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Attenuated Salmonella typhomurium; DNA vaccine; Melanoma; Therapeutic

Indexed keywords

BACTERIAL VECTOR; DNA VACCINE; HEAT SHOCK PROTEIN 70; TUMOR ANTIGEN; TYROSINASE RELATED PROTEIN 2; CANCER VACCINE; DOPACHROME ISOMERASE; HYBRID PROTEIN; ISOMERASE; LIVE VACCINE; PEPTIDE FRAGMENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ARTICLE; AUTOIMMUNITY; CANCER CELL; CANCER INHIBITION; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; DNA REPLICATION; DRUG EFFICACY; DRUG TARGETING; EMBRYO; EUKARYOTE; FEMALE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; MALE; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROKARYOTE; PROTEIN BINDING; PROTEIN DOMAIN; SALMONELLA TYPHIMURIUM; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY; TUMOR VOLUME; ANIMAL; C57BL MOUSE; CYTOTOXICITY; DRUG EFFECTS; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; MELANOMA, EXPERIMENTAL; MICROBIOLOGY; ORAL DRUG ADMINISTRATION; PATHOLOGY; PROTEIN ENGINEERING; SALMONELLA ENTERICA SUBSP. ENTERICA SEROVAR TYPHIMURIUM; T LYMPHOCYTE;

ADMINISTRATION, ORAL; ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CYTOTOXICITY, IMMUNOLOGIC; HSP70 HEAT-SHOCK PROTEINS; IMMUNOTHERAPY; INTRAMOLECULAR OXIDOREDUCTASES; LYMPHOCYTE ACTIVATION; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; PEPTIDE FRAGMENTS; PROTEIN ENGINEERING; RECOMBINANT FUSION PROTEINS; SALMONELLA TYPHIMURIUM; T-LYMPHOCYTES; VACCINES, ATTENUATED; VACCINES, DNA;

EID: 77953049636     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e3181cf23a6     Document Type: Article

References (38)

1. Ribas A. Update on immunotherapy for melanoma. J Natl Compr Canc Netw. 2006;4:687-694.
2. Timmerman JM, Levy R. Dendritic cell vaccines for cancer immunotherapy. Annu Rev Med. 1999;50:507-529.
3. Korman AJ, Peggs KS, Allison JP. Checkpoint blockade in cancer immunotherapy. Adv Immunol. 2006;90:297-339.
4. Ribas A, Hanson DC, Noe DA, et al. Tremelimumab (CP-675,206), a cytotoxic T lymphocyte associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer. Oncologist. 2007;12:873-883.
5. Sprent J, Schaefer M. Antigen-presenting cells for CD8+ T cells. Immunol Rev. 1990;117:213-234.
6. Wang RF, Rosenberg SA. Human tumor antigens for cancer vaccine development. Immunol Rev. 1999;170:85-100.
7. Perales MA, Wolchok JD. Melanoma vaccines. Cancer Invest. 2002;20:1012-1026.
8. Schneider J, Gilbert SC, Blanchard TJ, et al. Enhanced immunogenicity for CD8+ T cell induction and complete protective effcacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat Med. 1998;4: 397-402.
9. Collins SA, Guinn BA, Harrison PT, et al. Viral vectors in cancer immunotherapy: which vector for which strategy? Curr Gene Ther. 2008;8:66-78.
10. Luo Y, Zhou H, Mizutani M, et al. A DNA vaccine targeting Fos-related antigen 1 enhanced by IL-18 induces long-lived T-cell memory against tumor recurrence. Cancer Res. 2005;65: 3419-3427.
11. Xiang R, Mizutani N, Luo Y, et al. A DNA vaccine targeting survivin combines apoptosis with suppression of angiogenesis in lung tumor eradication. Cancer Res. 2005;65:553-561.
12. Luo Y, Zhou H, Mizutani M, et al. Transcription factor Fos-related antigen 1 is an effective target for a breast cancer vaccine. Proc Natl Acad Sci U S A. 2003;100:8850-8855.
13. Niethammer AG, Xiang R, Becker JC, et al. A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nat Med. 2002;8:1369-1375.
14. Higgins DE, Portnoy DA. Bacterial delivery of DNA evolves. Nat Biotechnol. 1998;16:138-139.
15. Lowrie DB. DNA vaccination exploits normal biology. Nat Med. 1998;4:147-148.
16. Fairweather NF, Chatfield SN, Charles IG, et al. Use of live attenuated bacteria to stimulate immunity. Res Microbiol. 1990;141:769-773.
17. Hormaeche CE. Live attenuated Salmonella vaccines and their potential as oral combined vaccines carrying heterologous antigens. J Immunol Methods. 1991;142:113-120.
18. Darji A, zur Lage S, Garbe AI, et al. Oral delivery of DNA vaccines using attenuated Salmonella typhimurium as carrier. FEMS Immunol Med Microbiol. 2000;27:341-349.
19. Rimoldi M, Chieppa M, Larghi P, et al. Monocyte-derived dendritic cells activated by bacteria or by bacteria-stimulated epithelial cells are functionally difierent. Blood. 2005;106: 2818-2826.
20. Javid B, MacAry PA, Oehlmann W, et al. Peptides complexed with the protein HSP70 generate effcient human cytolytic T-lymphocyte responses. Biochem Soc Trans. 2004;32(Pt 4): 622-625.
21. Delneste Y, Magistrelli G, Gauchat J, et al. Involvement of LOX-1 in dendritic cell-mediated antigen cross-presentation. Immunity. 2002;17:353-362.
22. Chen D, Androlewicz MJ. Heat shock protein 70 moderately enhances peptide binding and transport by the transporter associated with antigen processing. Immunol Lett. 2001;75: 143-148.
23. Bloom MB, Perry-Lalley D, Robbins PF, et al. Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma. JExpMed. 1997;185:453-459.
24. Wang RF, Appella E, Kawakami Y, et al. Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes. J Exp Med. 1996;184:2207-2216.
25. Parkhurst MR, Fitzgerald EB, Southwood S, et al. Identification of a shared HLA-A*0201-restricted T-cell epitope from the melanoma antigen tyrosinase-related protein 2 (TRP2). Cancer Res. 1998;58:4895-4901.
26. Wang RF, Johnston SL, Southwood S, et al. Recognition of an antigenic peptide derived from tyrosinase-related protein-2 by CTL in the context of HLA-A31 and -A33. J Immunol. 1998; 160:890-897.
27. Sun Y, Song M, Stevanovic S, et al. Identification of a new HLA-A (*)0201-restricted T-cell epitope from the tyrosinase-related protein 2 (TRP2) melanoma antigen. Int J Cancer. 2000;87:399-404.
28. Erdmann J. Immunology: lights, camera, infection. Nature. 2009;460:568-570.
29. Chieppa M, Rescigno M, Huang AY, et al. Dynamic imaging of dendritic cell extension into the small bowel lumen in response to epithelial cell TLR engagement. J Exp Med. 2006; 203:2841-2852.
30. DiGiandomenico A, Rao J, Goldberg JB. Oral vaccination of BALB/c mice with Salmonella enterica serovar typhimurium expressing Pseudomonas aeruginosa O antigen promotes increased survival in an acute fatal pneumonia model. Infect Immun. 2004;72:7012-7021.
31. Ye JX, Zhang YT, Zhang XG, et al. Recombinant attenuated Salmonella harboring 4-1BB ligand gene enhances cellular immunity. Vaccine. 2009;27:1717-1723.
32. Fu W, Chu L, Han X, et al. Synergistic antitumoral effects of human telomerase reverse transcriptase-mediated dual-apoptosis-related gene vector delivered by orally attenuated Salmonella enterica Serovar Typhimurium in murine tumor models. J Gene Med. 2008;10:690-701.
33. Yang N, Zhu X, Chen L, et al. Oral administration of attenuated S. typhimurium carrying shRNA-expressing vectors as a cancer therapeutic. Cancer Biol Ther. 2008;7:145-151.
34. Bauer H, Darji A, Chakraborty T, et al. Salmonella-mediated oral DNA vaccination using stabilized eukaryotic expression plasmids. Gene Ther. 2005;12:364-372.
35. Gahan ME, Webster DE, Wesselingh SL, et al. Impact of plasmid stability on oral DNA delivery by Salmonella enterica serovar Typhimurium. Vaccine. 2007;25:1476-1483.
36. Laus R, Graddis TJ, Hakim I, et al. Enhanced major histocompatibility complex class I-dependent presentation of antigens modified with cationic and fusogenic peptides. Nat Biotechnol. 2000;18:1269-1272.
37. Kim JH, Majumder N, Lin H, et al. Induction of therapeutic antitumor immunity by in vivo administration of a lentiviral vaccine. Hum Gene Ther. 2005;16:1255-1266.
38. Zhang H, Wang W, Li Q, et al. Fusion protein of ATPase domain of Hsc70 with TRP2 acting as a tumor vaccine against B16 melanoma. Immunol Lett. 2006;105:167-173.